Sarcoidosis: can tofacitinib slay the dragon?

Affiliations

¹ Division of Rheumatology, University of Illinois, Chicago, IL, USA. nsweiss@uic.edu.
² Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.

Comment

Nadera J Sweiss et al. Nat Rev Rheumatol. 2022 Oct.

. 2022 Oct;18(10):557-558.

doi: 10.1038/s41584-022-00832-1.

¹ Division of Rheumatology, University of Illinois, Chicago, IL, USA. nsweiss@uic.edu.
² Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.

No abstract available

Comment on

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Damsky W, et al. Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x. Nat Commun. 2022. PMID: 35668129 Free PMC article. Clinical Trial.

1. Damsky, W. et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat. Commun. 13, 3140 (2022). - DOI
1. Song, M. et al. Sarcoidosis and autoimmunity. Curr. Opin. Pulm. Med. 27, 448–454 (2021). - DOI
1. Baughman, R. P. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur. Respir. J. 58, 2004079 (2021). - DOI
1. Sweiss, N. J. et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 27, 49–56 (2010). - PubMed
1. Iwasaki, T. et al. Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis. Front. Immunol. https://doi.org/10.3389/fimmu.2022.901437 (2022). - DOI - PubMed - PMC